FIGO Cancer Report 2018 (Neerja Bhatla N, Aoki D, Sharma DN, Sankaranarayanan, R, et al: Cancer of the cervix uteri. International Journal of Gynecology and Obstetrics, 2018
Melamed A, Margul D J, Chen L. Survival after minimally invasive radical hysterectomy for early-stage cervical cancer. N Engl J Med. 2018; 379: 1905-14.
Cibula, Raspollini, Planchamp. et al. ESGO/ESTRO/ESP Guidelines for the management of patients with cervical cancer – Update 2023* , Int J Gynecol Cancer 2023
C. Marth , F. Landoni, S. Mahner , M. McCormack A. Gonzalez-Martin5 & N. Colombo, Cervical cancer: ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up,
Tewari KS, Sill MW, Long HJ, 3rd, et al. Improved survival with bevacizumab in advanced cervical cancer. N Engl J Med. 2014;.
Gupta S, Maheshwari A, Parab P, et al. Neoadjuvant chemotherapy followed by radical surgery versus concomitant chemotherapy and radiotherapy in patients with stage Ib2, IIa, or IIb squamous cervical cancer: a randomized controlled trial. J Clin Oncol. 2018
Salihi R, Leunen K, Moerman P, et al. Neoadjuvant weekly paclitaxel-carboplatin is effective in stage I-II cervical cancer. Int J Gynecol Cancer. 2017;
McCormack M., Gallardo Rincón D., Eminowicz G., LBA8 A randomised phase III trial of induction chemotherapy followed by chemoradiation compared with chemoradiation alone in locally advanced cervical cancer: The GCIG INTERLACE trial, ESMO Congress 2023.
Domenica Lorusso, Yang Xiang, Kosei Hasegawa et al. Pembrolizumab or placebo with chemoradiotherapy followed by pembrolizumab or placebo for newly diagnosed, high-risk, locally advanced cervical cancer (ENGOT-cx11/GOG-3047/KEYNOTE-A18): a randomised, double-blind, phase 3 clinical trial. Lancet. 2024 Apr 6;403(10434):1341-1350. doi: 10.1016/S0140-6736(24)00317-9.
Colombo N, Dubot C, Lorusso D, et al. Pembrolizumab for persistent, recurrent, or metastatic cervical cancer. N Engl J Med. 2021; 385
K. S. Tewari et al., Survival with Cemiplimab in Recurrent Cervical Cancer -EMPOWER-Cervical 1/GOG-3016/ ENGOT-cx9: N England J Med 2022
Vergote I, González-Martín A, Fujiwara K, et al . Tisotumab Vedotin as Second- or Third-Line Therapy for Recurrent Cervical Cancer N Engl J Med. 2024 Jul 4;391:44-55